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ABSTRACT 
 
p-synephrine is the active ingredient in Citrus aurantium which is 
a major component of weight loss preparations. A uterotrophic 
assay carried out by Arbo et al. on immature female mice 
demonstrated that p-synephrine could act as an antagonist at the 
oestrogen receptor. This warrants consideration because these 
formulations are used indiscriminately by young women. 17β-
oestradiol has a high affinity for the oestrogen receptor; 
consequently it was used as a benchmark against which the 
affinity of p-synephrine and the de novo designed non-steroidal 
molecules could be compared. Binding affinities of the p- 
synephrine molecules were relatively low (pKd= 4.5-5.0) 
compared to that of 17β-oestradiol (pKd 7.23). However, the de 
novo generated molecules had affinities ranging between 5.6-8.48. 
This gives a good indication that these molecules could potentially 
displace 17β-oestradiol from the oestrogen receptor ligand binding 
pocket and that they could be further developed for the treatment 
of breast cancer and osteoporosis.   
 
Introduction: 
Aesthetic and health motivated pressures to 
maintain acceptable weight height ratios have, and continue 
to provide impetus for the development of pharmacological 
agents targeted to treat obesity1. Drugs can only be used if 
proven effective and safe and these can only be prescribed by 
practitioners who understand obesity and its global 
management, and who are prepared to select, educate and 
follow-up their patients. 
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The 2004 Food and Drug Administration (FDA) ban on the 
inclusion of ephedrineanalogues in such preparations saw a 
concomitant increase in p- synephrine2containing products in 
which p-synephrine is present as the primary protoalkaloid in 
Citrus aurantium- the Bitter Orange, and in other citrus 
species. This consequent relative widespread use of Citrus 
aurantium containing products has led to the legitimate  
 
questioning of the safety profile of p-synephrine3. p-
synephrine is a sympathomimetic compound that is 
chemically similar to ephedrine and amphetamine (Ref. Fig. 
1). By virtue of its ability to stimulate the β3-adrenoreceptor, 
it has been associated with increased metabolism and 
oxidation of fats and consequently with weight loss3. 
However,β3-adrenoreceptor stimulation also 
explains the reports of increased blood pressure and 
tachyarrhythmia associated with prolonged use of p-
synephrine containing preparations4. Furthermore, a 2009 
uterotrophic assay carried out by Arbo et al.5 on immature 
female mice demonstrated the fact that p-synephrine 
possessed an anti-oestrogenic activity, which while being less 
than that exerted by ephedrine, still warrants consideration 
given the fact that these formulations are often used 
indiscriminately by young women, consequently carrying the 
potential of interference with hormonal routes, fertility, and 
female embryonic development. 
Since synephrine is a chiral compound it can exist 
in the dextro- (d-) and levo- (l-) forms. Clinically, it is sold as 
a racemate but it was found that the two different forms differ 
in pharmacological activity with (R)-(-)-synephrine being 
more active than its (S)-(+)-counterpart6. 
The oestrogen receptor (ER) forms part of the 
nuclear receptor superfamily, and falls into the class of 
steroid receptors7.  Steroid receptors mediate their action via 
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steroid hormones, such as 17β-oestradiol in the case of the 
ER. It is the predominant steroid hormone responsible for 
secondary sexual characteristics in females; thus it has a wide 
spectrum of functions, influencing most of the major organ 
systems in the body8. 
 
Figure 1: 2D structures of p-synephrine, Ephedrine and 
Amphetamine. 
p-Synephrine
 
        Ephedrine 
 
 
                   Amphetamine 
 
 
The discovery of the ER and the first anti-oestrogen 
opened a door to innovation in the field of therapy for breast 
cancer and osteoporosis9. Tamoxifen and Raloxifene are 
known as Selective Oestrogen Receptor Modulators 
(SERMs) and act as anti-oestrogens to reduce the incidence 
of breast cancer in pre- and postmenopausal women in the 
case of tamoxifen, and toreduce the risk of osteoporosis high 
in risk postmenopausal women in the case of raloxifene10.  
This in silico study seeks primarily to validate 
computationally Arbo et al’s assertion of affinity of p-
synephrine for the Oestrogen Receptor Ligand Binding 
Pocket (ER_LBP). Based on these results, this study also 
proposes the p-synephrine scaffold as a novel non-steroidal 
pharmacophore which could be utilised in the context of a de 
novo drug design study to propose lead molecules with 
demonstrable high affinity for the ER, and with the 
concomitant potential for ER antagonism and acceptable 
bioavailability suitable for the treatment of breast cancer and 
osteoporosis. 
 
 
 
Material and Methods: 
Crystallographic data was obtained from the Protein Data 
Bank with Brzozowski et al.’s deposition 1ERE11 describing 
the human ER ligand binding domain crystallised as a 
hexamere complexed with 17β-oestradiol resolved to 3.1Å 
being used as a template (Ref. Fig. 2(a)). 
All molecular modelling was performed using 
Sybyl-X1.112. In silico estimations of Ligand Binding 
Affinity (LBA) were performed using XSCOREv1.313, and 
de novo molecular design was carried out using 
LigBuilderv1.214. 
The 3D coordinates of 1ERE were read into Sybyl-
X1.112ensuring preservation of the bound coordinates of the 
complex. Molecular simplification of ER through removal of 
unnecessary chains and water molecules was done in order to 
reduce the computer intensiveness in subsequent calculations 
(Ref. Fig. 2(b)-(d)). 
Computational extraction of 17β-oestradiol from its 
cognate LBP in Sybyl-X1.112 allowed preservation of its 
bound co-ordinates. The separate files were exported into 
XSCOREv1.313 in order to estimate a predicted in silico 
affinity of the ligand for its endogenous receptor.  
This figure was established as a benchmark against which the 
affinity of p-synephrine and the de novo designed molecules 
could be compared. 
 
Figure 2(a): 1ERE hexamere where the different colours 
represent the different chains generated using VMD15 
  
 
 
Figure 2(b):  Simplified 1ERE depicting 17β-oestradiol 
bound to the ER generated using VMD15 
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Figure 2(c): ER void of ligand and water molecules 
generated using VMD15 
 
 
 
Figure 2(d): The extracted ligand, 17β-oestradiol 
generated using VMD15 
 
 
 
The 3Dstructures of the (R)- and (S)- isomers of p-
synephrine were generated using Sybyl-X1.112 (Ref. Fig. 3). 
The bioactive conformation of 17β-oestradiol was used as a 
template in a process that allowed the docked p-synephrine 
structures to assume numerous high affinity conformations 
within the ER_LBP (Ref. Fig. 4). These p-synephrine 
conformers were consequently identified, saved, and the 
Ligand Binding Energy (kcalmol-1) was calculated in Sybyl-
X1.112 for each conformer.  
Each conformation was subsequently individually 
exported to XSCOREv1.213and guided into the ER_LBP so 
that their affinity for the ER could be calculated and 
compared to that of 17β-oestradiol. 
 
 
 
Figure 3(a): 3D structure of the p-(R)-synephrine isomer 
generated using VMD15 
 
 
 
Figure 3(b): 3D structure of the p-(S)-synephrine isomer 
generated using VMD15 
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Figure 4: The top 21 binding p-(R)-Synephrine (top) and 
p-(S)-Synephrine (bottom) conformers generated using 
VMD15 
 
 
 
 
In the next part of the study, the p-synephrine 
conformer exhibiting a high computationally calculated 
affinity (pKd)and low binding energy (kcalmol-1) 
combinationwas identified as the pharmacophoric scaffold of 
choice for the de novo design of novel non-steroidal 
structures with the ability to occupy the 3D volume of the 
ER_LBP efficiently and with high affinity.  
To this end, the bound conformation of 17β-
oestradiol was once again invoked and used as a probe in 
order to establish the 3D volume of the ER_LBP together 
with the nature of the amino acid side chains delineating its 
perimeter.  
The selectedp-synephrine conformer was subjected 
to successive editing such that seed molecules capable of 
sustaining growth at pre-designated junctures (labelled H.spc) 
were created (Ref. Fig. 5) in an effort to be able to better 
identify which structural changes would have the greatest 
impact on LBA. 
Figure 5(a): Seed 1 
 
 
 
Figure 5(b):Seed 2 
 
 
Figure 5(c): Seed 3 
 
 
 
 
Figure 5(d): Seed 4 
 
 
 
Figure 5(e): Seed 5 
 
 
Figure 5(f): Seed 6 
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The seed structures were then introduced into the 
ER_LBP in an orientation identical to that of the selected p-
synephrine conformer. The growth of novel structures was 
then carried out using the GROW module of 
LigBuilderv1.214 according to a designed protocol that 
ensured chemical and synthetic feasibility.  
Furthermore, stringent limitations were placed on 
the nature of the molecular structures that were allowed to 
develop within the ER_LBP. Through the restriction of 
molecular weight, logP, and the amount of hydrogen bond 
donors and acceptors, it was ensured that all the obtained 
structures would lie well within Lipinski et al’s 
recommendations for ensuring bioavailability and that 
successive rounds of optimisation would not result in 
Lipinski Rule violators. 
 
Results:  
The in silico predicted LBA of 17β-oestradiol for 
the ER (PDB 1ERE) was 7.23, compared to those of the (R)- 
and (S)-p-synephrine conformers which ranged from pKd 4.5 
to 5.0 where higher values indicate greater LBA. The binding 
energies (kcalmol-1) were also quantified in SybylX1.1 for 
each conformer (Ref. Fig. 6). 
The implication of these results is that p-synephrine 
should only have a marginal affinity for the ER and that it 
would be incapable of displacing 17β-oestradiol from its 
cognate LBP in a competitive scenario.  
T he 3D image of the mapped ER_LBP and proposed 
pharmacophore based on the bound coordinates of 17β-
oestradiol are shown in figure 7. p-(R)-synephrine conformer 
10 as shown in Figure 6(a) was chosen as the best binding 
conformer as it has a high binding affinity and low binding 
energy, and consequently this structure was used as a scaffold 
for further studies.  
Application of the de novo design process on the 
prepared seed structures according to the GROW module 
resulted in molecules with a significant increase in affinity 
where estimated binding affinities ranging from pKd 6.5 to 
8.48. Five of the best binding molecules were selected as 
potential non-steroidal lead structures based on molecular 
weight, log P and LBA (Table1). 
 
 
 
 
 
 
Figure 6(a): Graph of Predicted LBA (pKd)/Binding Energy (kcalmol
-1
) for the 21 structural conformations 
of p-(R)-synephrine for the ER 
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Figure 6(b): Graph of Predicted LBA (pKd)/Binding Energy (kcalmol-1) for the 21 structural conformations of p-(S)-
synephrine for the ER 
  
 
Figure 7(a): 3D map of the ER_LBP as delineated in the 
crystallographic deposition 1ERE generated using 
VMD15, where hydrogen bond donor grids can be seen in 
blue, hydrogen bond acceptor grids are shown in red, 
while hydrophobic grids are shown in cyan 
 
 
 
 
 
 
 
 
 
Figure 7(b): Proposed pharmacophoric structure of 
potential high affinity ligands for the ER_LBPbased on 
the interactions forged between the bioactive 
conformation of 17β-oestradiol and the ER_LBP as 
delineated in PBD crystallographic deposition 1ERE. 
Graphics were generated using VMD15, and hydrogen 
bond donors can be seen in blue, hydrogen bond 
acceptors are shown in red, while hydrophobic regions 
are shown in cyan 
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Table 1. Five ligands with a high LBA for the ER_LBP shown below. Structural images were generated using MolSoft-
ICM. 
Seed 
No. 
Mol. 
No. 
Family No Chemical 
Formula 
Mol. Wt LogP pKd 3D structure 
2 1 <1> C19H21O2 281 3.96 8.25 
 
3 50 <3> C17H25O3 277 3.89 7.45 
 
4 1 <1> C18H25NO2 287 3.95 8.40 
 
5 35 <2> C17H2503 277 3.98 8.45 
 
BIOMIRROR  
 
12 BIOMIRROR                               ISSN 0976 – 9080 BM, an open access journal                                Volume 4(08) :5-12(2013)  
     
6 12 <2> C17H2203 274 3.73 8.43 
 
 
Discussion: 
Structural analysis and comparison of de novo 
designed ligands allowed the establishment of correlations 
between structure and affinity as follows; 
 LBA increased as the degree of saturation decreased. 
 
 LBA was higher for those ligands which were structurally 
compact as opposed to the more structurally open ligands 
which exhibited a lower binding affinity. 
 
 LBA was higher for those ligands which were rich in 
aromatic rings, when compared to their straight chain 
counter parts. 
 
 Ligands containing a terminal hydrogen bond accepting 
ammonium group have a higher affinity than their non-
terminal ammonium group counterparts. 
 
 Ligands containing a terminal hydroxyl group exhibit an 
affinity that is higher than similar ligands in which this 
hydroxyl group is replaced by a carbonyl group. 
The study is valuable for a number of reasons. It is 
indicative of the fact that p-synephrine is not likely to 
complete successfully with 17-βoestradiol for the ER_LBP.  
Thus, potentially there should be no concern for the inclusion 
ofp-synephrine in dietary products due toin silico estimations 
of low affinity for the ER. 
It is also important in that it has shown that the 
synephrine scaffold is of utility in the design of molecules 
capable of interacting successfully with the ER_LBP. The 
fact that a number of the de novo designed ligands have an 
affinity greater than that of 17-β oestradiol augurs well for 
the competitive antagonism of this latter from the ER_LBP.  
This may be useful in the context of the clinical requirement 
for partial or total antagonism of the ER for the treatment of 
breast cancer and osteoporosis. 
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